4,389 Shares in Waters Corporation $WAT Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new stake in Waters Corporation (NYSE:WAT) during the 3rd quarter, Holdings Channel reports. The firm bought 4,389 shares of the medical instruments supplier’s stock, valued at approximately $1,316,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in WAT. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Waters by 12.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,021 shares of the medical instruments supplier’s stock worth $2,800,000 after acquiring an additional 896 shares during the last quarter. Deroy & Devereaux Private Investment Counsel Inc. raised its position in Waters by 41.9% in the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 13,802 shares of the medical instruments supplier’s stock valued at $4,138,000 after purchasing an additional 4,077 shares during the period. Envestnet Asset Management Inc. lifted its stake in Waters by 5.0% during the second quarter. Envestnet Asset Management Inc. now owns 126,070 shares of the medical instruments supplier’s stock worth $44,004,000 after purchasing an additional 5,980 shares in the last quarter. Figure 8 Investment Strategies LLC boosted its position in shares of Waters by 46.4% during the third quarter. Figure 8 Investment Strategies LLC now owns 7,793 shares of the medical instruments supplier’s stock worth $2,336,000 after buying an additional 2,471 shares during the period. Finally, Union Bancaire Privee UBP SA acquired a new stake in shares of Waters in the third quarter valued at $1,624,000. Institutional investors and hedge funds own 94.01% of the company’s stock.

Waters Trading Down 1.3%

NYSE WAT opened at $370.47 on Friday. Waters Corporation has a 52 week low of $275.05 and a 52 week high of $423.00. The firm has a 50 day moving average of $390.42 and a two-hundred day moving average of $343.38. The stock has a market capitalization of $22.06 billion, a PE ratio of 34.05, a price-to-earnings-growth ratio of 3.14 and a beta of 1.16. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.41.

Waters (NYSE:WAT) last released its quarterly earnings data on Tuesday, November 4th. The medical instruments supplier reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.21 by $0.19. The business had revenue of $799.89 million during the quarter, compared to analysts’ expectations of $780.05 million. Waters had a net margin of 20.89% and a return on equity of 36.59%. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.93 EPS. Waters has set its FY 2025 guidance at 13.050-13.150 EPS and its Q4 2025 guidance at 4.450-4.550 EPS. As a group, research analysts expect that Waters Corporation will post 12.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on WAT. William Blair assumed coverage on Waters in a report on Monday, January 5th. They issued an “outperform” rating on the stock. Guggenheim began coverage on shares of Waters in a research note on Tuesday, January 6th. They set a “buy” rating and a $440.00 price target on the stock. HSBC began coverage on shares of Waters in a research report on Tuesday. They set a “buy” rating and a $460.00 price target on the stock. JPMorgan Chase & Co. upped their target price on shares of Waters from $300.00 to $325.00 and gave the stock a “neutral” rating in a research note on Thursday, October 9th. Finally, Wolfe Research raised shares of Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 price target for the company in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Waters currently has an average rating of “Moderate Buy” and a consensus target price of $398.61.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.